COMPANY

Therini Bio

Keywords: neurology ophthalmology retinal diseases antibody bispecific antibody alzheimer's disease Diabetic Macular Edema Diabetic Retinopathy Early Onset Alzheimer Disease THN391

Profile checked Oct 10, 2026

$39.0MRaised (2 yrs)2Trials (company is sponsor)3NIH grants

Raises and deals from press releases

Raise Series A · $39M · announced May 14, 2025 Company release ↗
Source quote
- May 14, 2025 · Company release ↗
  “Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline”

Raises announced in these releases: $39M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 17, 2025 Trial start Phase 1: A Study to Assess THN391 in Subjects With Alzheimer's Disease source ↗
May 14, 2025 Raise Private equity round — Series A: $39M (total, as published), announced May 14, 2025. Source: company's own press page. source ↗
May 14, 2025 Raise Series A · $39M source ↗
Dec 20, 2024 Trial start Phase 1: A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy. source ↗

Upcoming milestones

Mar 31, 2027 (ESTIMATED) · Phase 1 · A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy. · NCT06701721
Mar 31, 2027 (ESTIMATED) · Phase 1 · A Study to Assess THN391 in Subjects With Alzheimer's Disease · NCT06814730

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $39.0M. Last 2 years.

May 14, 2025 Private equity round — Series A: $39M (total, as published), announced May 14, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06701721	A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.	Phase 1	Recruiting	Dec 20, 2024	Mar 31, 2027 (estimated)
NCT06814730	A Study to Assess THN391 in Subjects With Alzheimer's Disease	Phase 1	Active, not recruiting	Jul 17, 2025	Mar 31, 2027 (estimated)

NIH awards 3

Annual award amounts. Total $3.0M.

Sep 7, 2023 NIH award 5U01AG073125-03 FY2023: $966,254 awarded for that fiscal year; activity U01 (OTHER_NIH); PI KANTOR, AARON B; recipient as written: THERINI BIO, INC., Sacramento, CA. Safety and Tolerability Studies for an A source ↗
Aug 30, 2022 NIH award 5U01AG073125-02 FY2022: $1,017,452 awarded for that fiscal year; activity U01 (OTHER_NIH); PI STAVENHAGEN, JEFFREY; recipient as written: THERINI BIO, INC., Sacramento, CA. Safety and Tolerability Studies f source ↗
Sep 16, 2021 NIH award 1U01AG073125-01 FY2021: $987,080 awarded for that fiscal year; activity U01 (OTHER_NIH); PI STAVENHAGEN, JEFFREY; recipient as written: THERINI BIO, INC., Sacramento, CA. Safety and Tolerability Studies for source ↗